Artella Solutions Inc., a leader in SaaS-driven cardiac monitoring and diagnostic intelligence, has announced a strategic partnership with PranaQ, a digital health company specializing in smart Home Sleep Testing (HST) solutions. This collaboration marks Artella’s expansion into sleep diagnostics, driven by the well-established clinical link between Obstructive Sleep Apnea (OSA) and Atrial Fibrillation (AFib). The integration will allow cardiology practices and hospital systems to order, track, and manage sleep studies directly through Artella’s Active State Monitoring platform, now branded as CARDIOSLEEP. Sepand Moshiri, Co-Founder and CEO of Artella Solutions, emphasized the value of streamlining care: “We built ARTELLA to simplify diagnostic workflows for clinicians. Integrating sleep testing into the platform gives practices a streamlined way to manage two highly correlated conditions with one partner.” The partnership enables a unified approach to diagnosing and managing both cardiac and sleep-related disorders, improving care coordination and patient outcomes. PranaQ’s FDA-cleared home sleep test system will be embedded within Artella’s existing diagnostic ecosystem, offering a seamless experience for providers. The solution supports remote patient monitoring with high accuracy, simple workflows, and rapid results—key advantages for busy cardiology practices. Jerry Chen, CEO of PranaQ, highlighted the mission behind the collaboration: “PranaQ is focused on improving access to sleep diagnostics. Partnering with ARTELLA brings our home sleep testing ecosystem into cardiology settings that see OSA every day but don’t always have an efficient pathway to diagnose it.” The connection between OSA and AFib is well-documented. Joseph Hashim, EVP of Commercialization & Strategy at Artella, noted, “In many patients, AFib is secondary to untreated obstructive sleep apnea. By diagnosing and treating OSA, clinicians can improve AFib management and, in some cases, eliminate the arrhythmia entirely.” This partnership empowers cardiology teams to identify underlying causes rather than merely treating symptoms. The integration offers significant benefits for both companies. Artella gains a new diagnostic vertical, expanding beyond cardiac monitoring into sleep medicine, while PranaQ gains access to Artella’s national network of healthcare providers. The combined platform provides a more complete picture of patient health, enabling earlier detection and more effective treatment of both conditions. Artella Solutions specializes in remote cardiac monitoring using patch technology and AI to detect rhythm abnormalities. Its platform is designed to support timely data review and workflow efficiency for physicians. PranaQ’s smart HST system is built to make sleep diagnostics faster, more accessible, and more accurate, with a focus on long-term monitoring and patient convenience. This partnership represents a major step in the convergence of cardiology and sleep medicine, two fields where undiagnosed OSA can significantly impact heart health. By combining their technologies, Artella and PranaQ are creating a more integrated, patient-centered model of care. The move also reflects a broader trend in digital health: the use of SaaS platforms to unify multiple diagnostic services under a single, efficient system. With the growing prevalence of both AFib and OSA, and the high rate of underdiagnosis, this collaboration has the potential to improve early detection, reduce complications, and lower long-term healthcare costs. As remote monitoring and AI-driven diagnostics become standard, partnerships like this one are likely to shape the future of preventive and chronic disease management. For more information, visit artellainc.com and pranaq.com.